Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
J Keith Joung
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Poseida Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Joung currently has an FCOI management plan for this grant for his interest in Transposagen Biopharmaceuticals. Poseida Therapeutics is a spin-off of Transposagen Biopharmaceuticals and Poseida will use Transposagen genome editing technology. This research project involves the use and development of genome editing technology and the research results from this project could affect the value of Poseida’s and Tranposagen’s technology. The Partners HealthCare Committee on Outside Activities (COA) Financial Interest Review Panel evaluated Dr. Joung’s financial interest and determined that, based on the close connection between the interests of the company and this research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
ADVANCING GENE-EDITING NUCLEASES FOR TARGETED GENOME MANIPULATION
Transcription activator-like effector (TALE) nucleases have transformed our ability to perform reverse genetics studies in zebrafish, an important model organism for studying human development and disease. The experiments of this proposal will advance and expand the toolbox of TALE-based technologies available for studying zebrafish including the development of artificial transcription factors, the generation of a comprehensive set of nucleases for disrupting the expression of zebrafish micro RNAs, and the optimization of several technologies for creating conditional alleles. Successful completion of the aims of this proposal will substantially enhance the utility of the zebrafish as an experimental model and provide important advances in the field of genome editing.
Filed on March 24, 2015.
Tell us what you know about J Keith Joung's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
J Keith Joung filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| J. Keith Joung | Cedars Sinai Medical Center | Conflict of Interest | Editas Medicine | >$600,000 |
| J. Keith Joung | Cedars Sinai Medical Center | Conflict of Interest | Editas Medicine | $100,000 - $149,999 |
| J Joung | Dana Farber Cancer Inst | Conflict of Interest | Editas Medicine | $20,000 - $39,999 |
| J. Keith Joung | Cedars Sinai Medical Center | Conflict of Interest | Transposagen Biopharmaceuticals | Value cannot be readily determined |
| J. Keith Joung | Cedars Sinai Medical Center | Conflict of Interest | Beam Therapeutics | Value cannot be readily determined |
| J Keith Joung | Massachusetts General Hospital | Conflict of Interest | Hera Testing Laboratories | Value cannot be readily determined |
| J. Keith Joung | Cedars Sinai Medical Center | Conflict of Interest | Beacon Genomics | Value cannot be readily determined |
| Keith Joung | Massachusetts General Hospital | Conflict of Interest | Blink Therapeutics | Value cannot be readily determined |
| J. Keith Joung | Cedars Sinai Medical Center | Conflict of Interest | Pairwise Plants | Value cannot be readily determined |
| Keith Joung | Massachusetts General Hospital | Conflict of Interest | EpiLogic Therapeutics | Value cannot be readily determined |
| J. Keith Joung | Cedars Sinai Medical Center | Conflict of Interest | Poseida Therapeutics | Value cannot be readily determined |
| J. Keith Joung | Cedars Sinai Medical Center | Conflict of Interest | EpiLogic Therapeutics | Value cannot be readily determined |
| J Joung | Dana Farber Cancer Inst | Conflict of Interest | Editas Medicine | Value cannot be readily determined |
| Keith Joung | Massachusetts General Hospital | Conflict of Interest | Endcadia | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.